RT Journal Article
SR Electronic
T1 Glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 131
OP 140
VO 67
IS 2
A2 Francis, Gary S.
A1 Roe, Matthew T.
A1 Sapp, Shelly K.
A1 Lincoff, A. Michael
YR 2000
UL http://www.ccjm.org/content/67/2/131.abstract
AB Glycoprotein (GP) Ilb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.